ZYMEWORKS INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
ZYMEWORKS INC. (ZYME) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-03-02
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $0.00.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-03-31 was $0.00.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $17.29M.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
- ZYMEWORKS INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $17.29M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $17.29M derived: sum of 3 quarters · filed 2026-03-02 | $17.29M 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $17.29M derived: sum of 2 quarters · filed 2025-11-06 | $17.29M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $17.29M 10-Q · filed 2025-08-07 | $17.29M 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |